Table 1.
Baseline characteristics
| Characteristics | CyberKnife® (n = 22) | Surgery (n = 26) |
|---|---|---|
| Sex | ||
| Male (n) | 18 | 24 |
| Female (n) | 4 | 2 |
| Age | ||
| Range | 43–80 | 37–77 |
| Median | 57 | 55 |
| Tumor diameters (cm) | ||
| Range | 1.6–9.5 | 1.8–13.7 |
| Median | 4.3 | 4.6 |
| Lesion site (n) | ||
| Left medial lobe | 6 | 5 |
| Left lateral lobe | 3 | 8 |
| Right anterior lobe | 8 | 3 |
| Right posterior lobe | 3 | 7 |
| Caudate lobe | 2 | 3 |
| AFP (before treatment) (ug/L) | ||
| Range | 2.8–7589 | 0.9–9840 |
| Median | 318.3 | 84.6 |
| Child-Pugh score | ||
| A | 10/22* | 23/26* |
| B | 10/22* | 3/26* |
| C | 2/22 | 0/26 |
| Systemic disease | ||
| Yes | 9/22* | 3/26* |
| No | 13/22* | 23/26* |
| Following treatment | ||
| No | 11/22 | 14/26 |
| Yes | 11/22 | 12/26 |
Notes:
*
P < 0.05. The remaining differences between the corresponding data were not statistically significant CyberKnife® (Accuray Incorporated, Sunnyvale, CA, USA).
Abbreviations: AFP, α-fetoprotein; n, number.